Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TempSLE (temperature-sensitive liquid embolic agent) is a medical agent designed for embolization procedures. It functions as a liquid embolic agent, meaning it is injected into blood vessels to block blood flow. Its temperature-sensitive property likely allows for controlled solidification or behavior within the body. It has been investigated for use in prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH), where it is combined with polyvinyl alcohol (PVA) microspheres to induce prostate necrosis. Additionally, TempSLE has been explored as a drug delivery system, capable of loading and releasing chemotherapy drugs like oxaliplatin, for transcatheter arterial chemoembolization (TACE) in conditions such as gastric cancer, where it effectively inhibits tumor cell proliferation and angiogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TempSLE.